Synthesis, characterization and antibacterial screening of 2,4-diaminopyrimidine pyrimethamine and trimethoprim silver complexes

Abstract

Air stable silver Ag(I) complexes of pyrimethamine and trimethoprim drugs have been synthesized and characterized by elemental analysis, Fourier transform infrared (FTIR) and ultraviolet visible (UV-Vis) spectroscopy, and conductivity measurement. The metal complexes formed a three and four coordinate geometry with the ligands acting as a monodentate molecule bonding to the silver ion in each case through the pyrimidine N (1) nitrogen. The complexes have non-electrolyte behaviour in dimethylformamide (DMF) solution with its low conductivity values. Silver complexes, their free ligands alongside the corresponding silver salts were screened against selected bacterial isolates. All the silver complexes showed enhanced antibacterial activities compared to their free ligands and potential antibacterial agents have been identified.

Construction and Docking Studies of Novel Pyrimido[4,5‐b]quinolines as Antimicrobial Agents

“…Literature surveys displayed that pyrimidine derivatives could act as antifungal through inhibiting DHFR enzyme [37–39] . Trimethoprim ( VI ) (Figure 1) is a diaminopyrimidine synthetic antimicrobial drug having DHFR inhibitory potential [40,41] . Many heterocyclic scaffolds have been found in the core structure of DHFR and/or DNA gyrase inhibitors as tetrazole, [42–44] triazole [45,46] .…”

“…[37][38][39] Trimethoprim (VI) (Figure 1) is a diaminopyrimidine synthetic antimicrobial drug having DHFR inhibitory potential. [40,41] Many heterocyclic scaffolds have been found in the core structure of DHFR and/or DNA gyrase inhibitors as tetrazole, [42][43][44] triazole. [45,46] Depending on the aforesaid studies, motivated by the versatility of quinolones and pyrimidines as vital moieties in a lot of FDA approved antimicrobial drugs, and in addition to our recent researches focusing on identifying novel bioactive agents, [7,[47][48][49][50][51][52][53][54][55][56][57][58][59] we combined quinolone moiety with pyrimidine ring in one hybrid forming novel series of pyrimidoquinolones adapting fragment based drug design technique.…”